$BDX (Becton, Dickinson and Company)

$BDX {{ '2015-08-06T11:43:12+0000' | timeago}} • Announcement

$BDX 3Q15 PR: Reported diluted earnings per share for quarter was $0.29 compared to $1.65 for 3Q14. Adjusted diluted EPS was $2.05, compared with $1.75 in 3Q14. This represents an increase of 17.1%, or 34.3% on a currency-neutral basis. For nine-month period, adjusted diluted earnings per share was $5.22 vs. $4.77 in 3Q14.

$BDX {{ '2017-12-29T16:54:30+0000' | timeago}} • Announcement

$BDX acquired $BCR. Beginning with 2Q18, $BDX will report a new Interventional segment structure, which will include a majority of Bard offerings, with the remainder being reported under the Medical segment.

$BDX {{ '2017-12-29T16:54:14+0000' | timeago}} • Announcement

$BDX has acquired $BCR. $BDX does not expect the acquisition to have a material impact on its financial results in 1Q18. $BDX expects the transaction to generate low-single digit accretion to adjusted EPS in FY18, and high-single digit accretion in FY19.

$BDX {{ '2017-12-29T16:53:59+0000' | timeago}} • Announcement

$BDX completed the acquisition of $BCR. Under the terms of the transaction, Bard became a wholly owned subsidiary of $BDX, and each outstanding share of Bard common stock was converted to the right to receive $222.93 in cash without interest, and 0.5077 of a share of $BDX common stock. Bard shares will cease trading and be delisted from the NYSE.

$BDX {{ '2017-12-28T12:35:48+0000' | timeago}} • Announcement

$BDX gets clearance from the Ministry of Commerce of the People's Republic of China (MOFCOM) to acquire $BCR. BD and Bard expect the proposed acquisition to close on Dec. 29. Separately, BD's proposed divestiture of its soft tissue core needle biopsy product line to Merit Medical is conditioned on MOFCOM approval of Merit as the purchaser.

$BDX {{ '2017-11-20T22:01:18+0000' | timeago}} • Announcement

$BDX has declared a quarterly dividend of $0.75 cents per common share, an increase of 2.7% from the previous quarter.  The dividend will be payable on Dec. 29, 2017 to holders of record on Dec. 8, 2017.

$MMSI {{ '2017-11-16T17:40:51+0000' | timeago}} • Announcement

$MMSI signed purchase agreement with $BDX for divestment assets in connection with its proposed acquisition of $BCR$MMSI expects the acquisition to provide incremental annual revenues of $42-48MM, and adjusted gross margins for the subject product lines of 60-70%. $MMSI expects deal to provide $0.10-0.19 in adjusted EPS accretion in FY18.

$MMSI {{ '2017-11-16T17:37:46+0000' | timeago}} • Announcement

$MMSI signed an asset purchase agreement with $BDX to buy certain assets which $BDX proposes to sell in connection with its proposed acquisition of $BCR. $MMSI proposes to buy the Aspira Pleural Effusion Drainage Kits and the Aspira Peritoneal Drainage System currently marketed by $BCR. The purchase price is $100MM.

$BDX {{ '2017-11-02T13:12:06+0000' | timeago}} • Infographic

$BDX Becton, Dickinson and Company Earnings AlphaGraphic: Q4 2017 Highlights

$BDX {{ '2017-11-02T11:15:18+0000' | timeago}} • Announcement

On a stand-alone basis, $BDX expects FY18 revenues to increase 5-6% as reported, or 4-5% on a currency-neutral basis. Adjusted EPS is predicted to be between $10.55 and $10.65 on a stand-alone basis, which represents growth of about 12%.

$BDX {{ '2017-11-02T11:09:45+0000' | timeago}} • Announcement

$BDX reported quarterly revenues of $3.166Bil for 4Q17, down 2% YoY, primarily due to the divestiture of the Respiratory Solutions business that was completed in October 2016. On a comparable, currency-neutral basis, revenues for the quarter grew 4.4%.

$BDX {{ '2017-11-02T11:04:23+0000' | timeago}} • Announcement

Medical technology company $BDX reported a jump in 4Q17 net income to $289MM, or $1.24 per share, compared to last year's $19MM, or $0.09 per share. This increase is primarily due to restructuring and other charges incurred in the prior-year due to the acquisition of CareFusion. On an adjusted basis, EPS grew 13.2% to $2.40.

$BDX {{ '2017-09-29T15:36:16+0000' | timeago}} • Announcement

Medical technology company $BDX has named Timothy M Ring and David F Melcher to its BoD, following completion the company’s acquisition of CR Bard Inc. Ring has been serving as Chairman and CEO of Bard since August 2003. Melcher, also a director of Bard, is President and CEO of the Aerospace Industries Association.

$BDX {{ '2017-08-15T12:16:07+0000' | timeago}} • Announcement

$BDX obtained 510(k) clearance from the U.S. FDA for the BD Bactec Standard Aerobic and Standard Anaerobic blood culture bottles in plastic. This marks further expansion of the blood culture bottles available in plastic across $BDX's industry-leading BD Bactec platform.

$BCR {{ '2017-08-09T13:54:30+0000' | timeago}} • Announcement

$BCR and $BDX have announced that they have received the approval of $BCR’s shareholders for the proposed acquisition of $BCR by $BDX in a stock and cash transaction. The proposed transaction remains subject to other conditions and approvals, and is presently expected to close in the fourth calendar quarter of 2017.

$BDX {{ '2017-07-19T13:58:34+0000' | timeago}} • Announcement

$BDX received 510(k) clearance from the FDA for the BD FACSLyric flow cytometer system, an easy-to-use in vitro diagnostic (IVD) system, for use with BD Multitest assays for immunological assessment of individuals and patients having or suspected of having immune deficiency.

$GS {{ '2017-07-19T11:22:37+0000' | timeago}} • Webcast

$GS advised a number of important transactions that were announced during 2Q17, including $BCR's $24Bil sale to $BDX. $AMZN's $13.7Bil acquisition of $WFM, and $DFT's $7.6Bil merger with $DLR.

$BDX {{ '2017-06-12T07:19:32+0000' | timeago}} • Announcement

$BDX and $BCR received a request for additional information from the Federal Trade Commission in connection with BD's pending acquisition of C.R. Bard. In April 2017, BD agreed to buy Bard in a $24Bil transaction. Both companies expect to get regulatory approvals and close the transaction in the fall of 2017.

$BDX {{ '2017-05-02T10:50:46+0000' | timeago}} • Announcement

$BDX now expects FY17 EPS of $7.73-7.83, which represents growth of about 72-74%. On a currency-neutral basis, $BDX still sees adjusted EPS of $9.70-9.80, which includes an estimated 1.5 points of dilution related to the Respiratory Solutions divestiture. Including negative foreign current impact, $BDX still sees adjusted EPS of $9.35-9.45.

$BDX {{ '2017-05-02T10:47:45+0000' | timeago}} • Announcement

$BDX still expects FY17 revenue to decrease 3.5-4%, primarily due to the divestiture of the Respiratory Solutions business. The company continues to estimate that revenues for FY17 to increase 4.5-5.0% on a comparable, currency-neutral basis that excludes Respiratory Solutions and other divestitures that closed in FY16.

$BDX {{ '2017-05-02T10:46:32+0000' | timeago}} • Announcement

As a result of transformation in the U.S. dispensing business within Medication Management Solutions, $BDX's accounting for revenue recognition will change to reflect the new dispensing business model. $BDX sees an unfavorable impact to FY17 of about $50-60MM to revenues and about $0.20-0.25 to adjusted EPS.

Recent Transcripts

UNH (UnitedHealth Group Incorporated)
Tuesday, January 16 2018 - 1:45pm
TRXC (TransEnterix, Inc.)
Thursday, November 9 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
CCXI (ChemoCentryx, Inc.)
Tuesday, November 7 2017 - 10:00pm
NKTR (Nektar Therapeutics)
Tuesday, November 7 2017 - 10:00pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
HAE (Haemonetics Corporation)
Tuesday, November 7 2017 - 1:00pm
HRC (Hill-Rom Holdings, Inc.)
Friday, November 3 2017 - 12:00pm
TFX (Teleflex Incorporated)
Thursday, November 2 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
QCOM (QUALCOMM Incorporated)
Wednesday, November 1 2017 - 8:45pm
STE (Steris Plc)
Wednesday, November 1 2017 - 2:00pm
AGN (Allergan plc)
Wednesday, November 1 2017 - 12:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
SNE (Sony Corporation)
Tuesday, October 31 2017 - 7:30am
OFIX (Orthofix International N.V.)
Monday, October 30 2017 - 8:30pm
OMCL (Omnicell, Inc.)
Thursday, October 26 2017 - 8:30pm
RMD (ResMed Inc.)
Thursday, October 26 2017 - 8:30pm
SYK (Stryker Corporation)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm

AlphaGraphics you may like